Moleculin Biotech (MOL) Price & Analysis

Compare

3 Followers

MOL Stock Chart & Stats

Day’s Range― - ―

52-Week Range€6.45 - €6.60

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

$10.10M

Enterprise Value-€2.45M

Total Cash (Recent Filing)$7.56M

Total Debt (Recent Filing)$292.00K

Price to Earnings (P/E)―

Beta-1.40

Next Earnings

Nov 17, 2025

EPS Estimate

-0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.42

Shares Outstanding30,286,167

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.24

Enterprise Value/Revenue-19.44

Enterprise Value/Gross Profit87.48

Enterprise Value/Ebitda0.09

Forecast

1Y Price Target

$5.65

Price Target Upside-12.46% Downside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe pivotal Phase 3 MIRACLE study remains on track to deliver initial data, potentially providing significant insights into the efficacy and safety of the treatment by year's end.

Preclinical DataPromising preclinical data support the potential of annamycin as a therapeutic agent for the treatment of liver cancers.

Therapeutic PotentialAnnamycin achieved a 50% complete remission rate in a similar Phase 2 trial, suggesting potential effectiveness in the current study.

Bears Say

Financial PerformanceMoleculin Biotech announced 2Q25 financial results, posting EPS of ($0.49), compared to the estimate of ($0.41).

Stock TradingMBRX shares traded down following announcement of a warrant inducement transaction that brought in $6M in gross proceeds.

Moleculin Biotech News

Moleculin Biotech accelerates recruitment in Phase 3 MIRACLE trial

Moleculin Biotech (MBRX) announced updates to its active site status and recruitment for its pivotal Phase 2B/3, multi-center,...

10d ago

MBRX

Moleculin Biotech doses first EU patient in Phase 3 MIRACLE trial

Moleculin Biotech (MBRX) enrolled the first two subjects, and treated one, in the European Union in its pivotal...

11d ago

MBRX

Moleculin Biotech announces exercise of warrants for $6M gross proceeds

Moleculin Biotech (MBRX) entered into agreements with certain holders of its existing warrants for the immediate exercise of...

22d ago

MBRX

Moleculin Biotech announces OS data from Phase 1B/2 clinical trial in AML

Moleculin Biotech (MBRX) announced the completion of its Phase 1B/2 clinical trial evaluating Annamycin in combination with Cytarabine...

23d ago

MBRX

Moleculin Biotech’s Strategic Expansion and Promising Data Support Buy Rating

H.C. Wainwright analyst Sara Nik reiterated a Buy rating on Moleculin Biotech today and set a price target...

9d ago

MBRX

Moleculin Biotech Expands Global Phase 2B/3 Trial

Moleculin Biotech ( ($MBRX) ) has provided an update. On September 9, 2025, Moleculin Biotech announced updates on...

10d ago

MBRX

Moleculin Biotech Releases New Corporate Presentation

Moleculin Biotech ( ($MBRX) ) has issued an announcement. On September 8, 2025, Moleculin Biotech, Inc. used a...

11d ago

MBRX

Moleculin Biotech Begins Phase 2B/3 MIRACLE Trial Enrollment

Moleculin Biotech ( ($MBRX) ) just unveiled an announcement. On September 8, 2025, Moleculin Biotech announced the enrollment...

11d ago

MBRX

Promising Annamycin Trials Boost Moleculin Biotech’s Outlook Amidst Share Volatility

Moleculin Biotech, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from...

15d ago

MBRX

Moleculin Biotech Secures $6 Million Through Warrant Agreement

Moleculin Biotech ( ($MBRX) ) has shared an update. On August 27, 2025, Moleculin Biotech entered into an...

21d ago

MBRX

Optimistic Buy Rating for Moleculin Biotech Based on Promising Annamycin Data and Future Potential

Sara Nik, an analyst from H.C. Wainwright, reiterated the Buy rating on Moleculin Biotech. The associated price target...

23d ago

MBRX

Moleculin Biotech Completes Promising Annamycin Trial

The latest update is out from Moleculin Biotech ( ($MBRX) ). On August 27, 2025, Moleculin Biotech announced...

23d ago

MBRX

Moleculin Biotech Holds 2025 Annual Stockholders Meeting

The latest update is out from Moleculin Biotech ( ($MBRX) ). On August 18, 2024, Moleculin Biotech held...

1M ago

MBRX

Moleculin Biotech Releases New Corporate Presentation

Moleculin Biotech ( ($MBRX) ) has provided an update. On August 18, 2025, Moleculin Biotech, Inc. announced the...

1M ago

MBRX

MOL FAQ

What was Moleculin Biotech’s price range in the past 12 months?

Moleculin Biotech lowest stock price was €6.45 and its highest was €6.60 in the past 12 months.

What is Moleculin Biotech’s market cap?

Moleculin Biotech’s market cap is $10.10M.

When is Moleculin Biotech’s upcoming earnings report date?

Moleculin Biotech’s upcoming earnings report date is Nov 17, 2025 which is in 59 days.

How were Moleculin Biotech’s earnings last quarter?

Moleculin Biotech released its earnings results on Aug 13, 2025. The company reported -€0.419 earnings per share for the quarter, missing the consensus estimate of -€0.368 by -€0.051.

Is Moleculin Biotech overvalued?

According to Wall Street analysts Moleculin Biotech’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Moleculin Biotech pay dividends?

Moleculin Biotech does not currently pay dividends.

What is Moleculin Biotech’s EPS estimate?

Moleculin Biotech’s EPS estimate is -0.22.

How many shares outstanding does Moleculin Biotech have?

Moleculin Biotech has 30,286,167 shares outstanding.

What happened to Moleculin Biotech’s price movement after its last earnings report?

Moleculin Biotech reported an EPS of -€0.419 in its last earnings report, missing expectations of -€0.368. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Moleculin Biotech?

Currently, no hedge funds are holding shares in DE:MOL

Company Description

Moleculin Biotech

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

Moleculin Biotech (MOL) Earnings & Revenues

Historic Earnings Reports

MOL Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects significant progress in clinical trials and regulatory approvals, particularly for Annamycin. New patents and drug names bolster future market positioning. However, financial constraints and potential EU approval delays pose challenges.View all DE:MOL earnings summaries

MOL Stock 12 Month Forecast

Average Price Target

€5.65

▼(-12.46% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","11":"€11","4.25":"€4.25","6.5":"€6.5","8.75":"€8.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10.1578788,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€10.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.646087633,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€5.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.3859596,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€3.39</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,4.25,6.5,8.75,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.45,6.735221446153846,7.020442892307693,7.305664338461539,7.590885784615385,7.8761072307692315,8.161328676923077,8.446550123076923,8.73177156923077,9.016993015384616,9.302214461538462,9.587435907692308,9.872657353846154,{"y":10.1578788,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.45,6.3881605871538465,6.326321174307693,6.264481761461538,6.2026423486153845,6.140802935769231,6.078963522923077,6.017124110076923,5.955284697230769,5.893445284384615,5.8316058715384615,5.769766458692307,5.707927045846153,{"y":5.646087633,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.45,6.214304584615385,5.9786091692307695,5.742913753846154,5.507218338461539,5.271522923076923,5.035827507692308,4.800132092307693,4.564436676923077,4.328741261538461,4.093045846153846,3.857350430769231,3.6216550153846154,{"y":3.3859596,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.45,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >